Revance Therapeutics (RVNC) Now Covered by Guggenheim

Among holders that decreased their positions, 11 sold out of the stock Revance Therapeutics, Inc. (NASDAQ:RVNC). The Illinois-based Northern Trust has invested 0% in Revance Therapeutics, Inc. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. Proshare Ltd Liability invested in 17,521 shares. Swiss Commercial Bank stated it has 0% in Revance Therapeutics, Inc. Waddell Reed Financial has 223,900 shares for 0.01% of their portfolio. (RVNC) to generate earnings per share of $3.73 in 2017. Therefore 90% are positive. The Manufacturers Life Insurance Company grew its stake in Revance Therapeutics by 7.5% in the second quarter. FMR LLC acquired a new stake in Revance Therapeutics during the fourth quarter valued at about $2,070,000. Moreover, Geode Cap Mngmt Ltd has 0% invested in Revance Therapeutics, Inc. $38.75's average target is 19.32% above currents $32.475 stock price. Revance Therapeutics has a twelve month low of $15.85 and a twelve month high of $37.20. Aegis Capital maintained the shares of RVNC in report on Thursday, June 8 with "Buy" rating. Guggenheim initiated the shares of RVNC in report on Monday, November 23 with "Buy" rating. The firm earned "Buy" rating on Tuesday, July 25 by Piper Jaffray. Also, CEO L Daniel Browne sold 7,600 shares of the company's stock in a transaction that occurred on Wednesday, November 22nd. Revance Therapeutics has an average rating of "Buy" and a consensus target price of $40.75. (NASDAQ:RVNC). Wellington Mngmt Grp Incorporated Ltd Liability Partnership has invested 0.01% in Revance Therapeutics, Inc. Piper Jaffray maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) has "Buy" rating given on Thursday, July 20 by Cantor Fitzgerald. (NASDAQ:RVNC) rating on Thursday, November 16. The NASDAQ-listed company saw a recent bid of $33.65 on volume of 2.24 million shares. The firm has "Buy" rating given on Tuesday, October 24 by Cantor Fitzgerald. The rating was initiated by Guggenheim with "Buy" on Tuesday, December 5. They expect $-0.95 earnings per share, 0.00% or $0.00 from last year's $-0.95 per share. The shares were sold at an average price of $23.58, for a total value of $179,208.00. During the same period in the previous year, the company posted ($0.64) earnings per share. equities analysts anticipate that Revance Therapeutics will post -3.73 earnings per share for the current fiscal year.

RVNC has been the subject of a number of other research reports.

The stock decreased 3.49% or $1.175 during the last trading session, reaching $32.475. It has outperformed by 3.70% the S&P500. The company has market cap of $1.01 billion.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. Russell Investments Group Ltd. acquired a new stake in Revance Therapeutics during the fourth quarter valued at about $174,000. A negative earnings surprise will usually result in a decline in share price. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. According to the most recent data, Oclaro, Inc. has a 52-week high of $11.30 and a 52-week low of $5.86. More interesting news about Revance Therapeutics, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.